BR112022024262A2 - Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april - Google Patents
Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a aprilInfo
- Publication number
- BR112022024262A2 BR112022024262A2 BR112022024262A BR112022024262A BR112022024262A2 BR 112022024262 A2 BR112022024262 A2 BR 112022024262A2 BR 112022024262 A BR112022024262 A BR 112022024262A BR 112022024262 A BR112022024262 A BR 112022024262A BR 112022024262 A2 BR112022024262 A2 BR 112022024262A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- april
- methods
- iga nephropathy
- binding antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062704831P | 2020-05-29 | 2020-05-29 | |
| PCT/US2021/035011 WO2021243298A1 (en) | 2020-05-29 | 2021-05-28 | Methods of treating iga nephropathy with an april binding antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024262A2 true BR112022024262A2 (pt) | 2023-02-23 |
Family
ID=78722933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024262A BR112022024262A2 (pt) | 2020-05-29 | 2021-05-28 | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210379183A1 (https=) |
| EP (1) | EP4157339A4 (https=) |
| JP (1) | JP7843248B2 (https=) |
| KR (1) | KR20230017223A (https=) |
| CN (1) | CN115996748A (https=) |
| AU (1) | AU2021279035A1 (https=) |
| BR (1) | BR112022024262A2 (https=) |
| CA (1) | CA3179812A1 (https=) |
| IL (1) | IL298370A (https=) |
| MX (1) | MX2022014995A (https=) |
| WO (1) | WO2021243298A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| AU2023366516A1 (en) | 2022-10-28 | 2025-05-15 | Aduro Biotech Holdings, Europe B.V. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| JP2025536433A (ja) * | 2022-11-07 | 2025-11-05 | サンレノ セラピューティクス （シャンハイ） リミテッド | ＩｇＡ腎症を治療するためのエンドセリン受容体アンタゴニストとグルココルチコイドとの組み合わせ |
| WO2026050274A2 (en) * | 2024-08-27 | 2026-03-05 | Paragon Therapeutics, Inc. | April binding proteins, compositions, and methods of use thereof |
| WO2026067804A1 (zh) * | 2024-09-30 | 2026-04-02 | 信立泰(成都)生物技术有限公司 | 一种抗april抗体或其抗原结合片段及用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| WO2007142667A2 (en) * | 2005-10-13 | 2007-12-13 | Human Genome Sciences, Inc. | Treatment of patients with autoantibody positive disease |
| CN101678106B (zh) * | 2007-03-27 | 2013-06-05 | 津莫吉尼蒂克斯公司 | 用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合 |
| CA2738243C (en) * | 2008-10-29 | 2020-09-29 | Wyeth Llc | Formulations of single domain antigen binding molecules |
| CA2754127C (en) * | 2009-03-02 | 2017-04-18 | Stichting Top Institute Pharma | Antibodies against a proliferating inducing ligand (april) |
| NZ602685A (en) * | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| JP2018534295A (ja) * | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
| JOP20170017B1 (ar) * | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| WO2018201064A1 (en) * | 2017-04-28 | 2018-11-01 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CA3079946A1 (en) * | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
-
2021
- 2021-05-28 WO PCT/US2021/035011 patent/WO2021243298A1/en not_active Ceased
- 2021-05-28 CN CN202180046732.2A patent/CN115996748A/zh active Pending
- 2021-05-28 US US17/334,590 patent/US20210379183A1/en active Pending
- 2021-05-28 KR KR1020227043773A patent/KR20230017223A/ko active Pending
- 2021-05-28 BR BR112022024262A patent/BR112022024262A2/pt unknown
- 2021-05-28 IL IL298370A patent/IL298370A/en unknown
- 2021-05-28 JP JP2022573609A patent/JP7843248B2/ja active Active
- 2021-05-28 AU AU2021279035A patent/AU2021279035A1/en active Pending
- 2021-05-28 EP EP21813022.7A patent/EP4157339A4/en active Pending
- 2021-05-28 MX MX2022014995A patent/MX2022014995A/es unknown
- 2021-05-28 CA CA3179812A patent/CA3179812A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115996748A (zh) | 2023-04-21 |
| WO2021243298A1 (en) | 2021-12-02 |
| MX2022014995A (es) | 2023-02-09 |
| EP4157339A4 (en) | 2024-08-07 |
| AU2021279035A1 (en) | 2023-02-02 |
| CA3179812A1 (en) | 2021-12-02 |
| IL298370A (en) | 2023-01-01 |
| EP4157339A1 (en) | 2023-04-05 |
| JP7843248B2 (ja) | 2026-04-09 |
| KR20230017223A (ko) | 2023-02-03 |
| JP2023527563A (ja) | 2023-06-29 |
| US20210379183A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022024262A2 (pt) | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april | |
| MX2024001803A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| BR112021011431A2 (pt) | Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit | |
| BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| BR112021008873A8 (pt) | Formulação | |
| CR20200566A (es) | Anticuerpos anti-sirpa y metodos de utilización de los mismos | |
| BR112019008426A2 (pt) | anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| MX393951B (es) | Anticuerpos antisortilina y métodos para su uso. | |
| BR112019023898A2 (pt) | método para tratamento de câncer gástrico, uso de um anticorpo e composição | |
| BR112022023088A2 (pt) | Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| NI201000281A (es) | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. | |
| ECSP21022299A (es) | Anticuerpos de anti-cd33 y métodos para usarlos | |
| BR112017005517A2 (pt) | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes | |
| BR112018072066A2 (pt) | moléculas de ligação específicas para fcgamariia e uso das mesmas | |
| MX2020013428A (es) | Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana. | |
| CO2021015254A2 (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos | |
| BR112019004990A2 (pt) | anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo | |
| BR112021013397A2 (pt) | Anticorpos anti-tigit | |
| BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
| CR20220329A (es) | Anticuerpos anti–mertk y metodos de uso de los mismos | |
| ECSP22056627A (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
| MX2020013172A (es) | Anticuerpos anti-siglec-7 y sus metodos de uso. |